CANTARGIA AB 

Cantargia AB (publ), a biotechnology company, develops antibody-based treatments for life threatening diseases. The company is developing CAN04 (nadunolimab), an interleukin-1 receptor accessory protein (IL1RAP) binding antibody, which is in Phase II clinical trial for the treatment of pancreatic cancer, non-small cell lung cancer, and triple-negative breast cancer; and CAN10, an antibody against IL1RAP, which is in preclinical phase for the treatment of autoimmune and inflammatory diseases, including systemic sclerosis and myocarditis. It also develops CANxx, an IL1RAP-based antibody platform. The company has collaboration agreements with Patheon Biologics B.V. and BioWa Inc. for the manufacture and production of CAN04; and GEICAM, Spanish breast cancer group. Cantargia AB (publ) was incorporated in 2009 and is based in Lund, Sweden.